Rapport Therapeutics (RAPP) Net Cash Flow (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Net Cash Flow data on file, last reported at $25.4 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $25.4 million, up 3080.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.5 million (up 222.74% YoY), and the FY2025 annual result was -$4.2 million, up 68.82% from the prior year.
• Net Cash Flow grew to $25.4 million in Q1 2026 per RAPP's latest filing, from -$198.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $196.3 million in Q3 2025 and troughed at -$198.7 million in Q4 2025.
• A 4-year average of -$124272.7 and a median of $4.1 million in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow plunged 1236.09% in 2025, then soared 3080.35% in 2026.
• A 4-year view of Net Cash Flow shows it stood at -$89.2 million in 2023, then surged by 119.62% to $17.5 million in 2024, then sank by 1236.09% to -$198.7 million in 2025, then jumped by 112.79% to $25.4 million in 2026.
• Business Quant data shows RAPP's Net Cash Flow at $25.4 million in Q1 2026, -$198.7 million in Q4 2025, and $196.3 million in Q3 2025.